Extended trial tests drug for debilitating skin disease

NCT ID NCT05366855

Terminated Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study aimed to evaluate the long-term safety and effectiveness of an investigational drug called imsidolimab for adults with generalized pustular psoriasis, a severe and painful skin condition. It was an extension of a previous trial, following participants who had already received the drug to see how well it controlled their symptoms over time and how many experienced disease flare-ups. The study was terminated early and enrolled 42 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Site 10-101

Ann Arbor, Michigan, 48109, United States
Site 10-102

Springville, Utah, 84663, United States
Site 10-105

Louisville, Kentucky, 40217, United States
Site 10-108

Dallas, Texas, 75231, United States
Site 10-109

Largo, Florida, 33770, United States
Site 16-101

Paris, 75010, France
Site 16-102

Nantes, 44093, France
Site 17-102

Bad Bentheim, 48455, Germany
Site 17-103

Hanau, 63450, Germany
Site 17-104

Bonn, 53127, Germany
Site 17-105

Würzburg, 97080, Germany
Site 24-101

Barcelona, 08036, Spain
Site 24-102

Madrid, 28040, Spain
Site 24-103

Madrid, 28041, Spain
Site 24-104

Las Palmas de Gran Canaria, 35010, Spain
Site 24-105

Valencia, 46026, Spain
Site 30-101

Rzeszów, 35-055, Poland
Site 30-102

Wroclaw, 50-566, Poland
Site 30-103

Ossy, 42-624, Poland
Site 30-104

Krakow, 30-074, Poland
Site 30-105

Lodz, 90-265, Poland
Site 31-101

Cluj-Napoca, 400006, Romania
Site 31-102

Bucharest, 020125, Romania
Site 31-103

Iași, 700111, Romania
Site 33-101

Kayseri, 38039, Turkey (Türkiye)
Site 33-102

Ankara, 06560, Turkey (Türkiye)
Site 33-103

Bursa, 16059, Turkey (Türkiye)
Site 33-104

Antalya, 07070, Turkey (Türkiye)
Site 33-105

Istanbul, 24093, Turkey (Türkiye)
Site 33-106

Istanbul, 34010, Turkey (Türkiye)
Site 35-102

Melbourne, Victoria, 3128, Australia
Site 42-101

Kuala Lumpur, 50586, Malaysia
Site 42-102

Muar town, Johor, 84000, Malaysia
Site 42-103

Putrajaya, 62250, Malaysia
Site 42-104

Kuala Lumpur, 56000, Malaysia
Site 42-105

Kota Bharu, Kelantan, 15586, Malaysia
Site 42-106

Johor Bahru, Johor, 80100, Malaysia
Site 42-107

Johor Bahru, Johor, 81100, Malaysia
Site 42-108

Kuching, Sarawak, 93586, Malaysia
Site 42-109

Batu Caves, Selangor, 59100, Malaysia
Site 42-110

Kuala Lumpur, 59100, Malaysia
Site 45-101

Seoul, 05505, South Korea
Site 45-102

Busan, 49241, South Korea
Site 45-103

Seoul, 06591, South Korea
Site 45-104

Seoul, 03722, South Korea
Site 46-101

Bangkok, 10400, Thailand
Site 46-102

Chiang Mai, 50200, Thailand
Site 46-103

Pathum Thani, 12120, Thailand
Site 46-104

Khon Kaen, 40002, Thailand
Site 59-101

Tbilisi, 0160, Georgia
Site 59-102

Tbilisi, 0112, Georgia
Site 59-103

Tbilisi, 0179, Georgia
Site 59-104

Batumi, 6000, Georgia
Site 59-105

Tbilisi, 0160, Georgia
Site 62-101

Sfax, 3000, Tunisia
Site 62-102

Sousse, 4000, Tunisia
Site 62-103

Tunis, 1007, Tunisia
Site 63-101

Kaohsiung City, 83301, Taiwan
Site 63-102

Taipei, 11696, Taiwan
Site 63-103

New Taipei City, 23561, Taiwan
Site 63-104

Taipei, 11217, Taiwan
Site 63-105

Taipei, 100225, Taiwan
Site 64-101

Marrakesh, 40000, Morocco
Site 64-102

Oujda, 60000, Morocco
Site 64-103

Casablanca, 20360, Morocco

Conditions

Explore the condition pages connected to this study.

GENERALIZED PUSTULAR PSORIASIS